检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]第二军医大学药学院药物化学教研室,上海200433
出 处:《药学实践杂志》2014年第3期191-194,共4页Journal of Pharmaceutical Practice
基 金:国家自然科学基金(21172260)
摘 要:目的合成(E)-6-甲氧基-1-(3,4,5-三甲氧基苯亚甲基)-1,2,3,4-四氢-2-萘醇及其对映异构体,测定其晶体结构,并考察其生物活性。方法以2,6-二甲氧基萘为起始原料,经还原及Knoevenael缩合制得中间体萘酮,再以CBS不对称催化还原分别制得R、S构型的目标化合物。采用单晶X-衍射测定其晶体结构,并测试其微管蛋白的抑制活性及体外抗肿瘤活性。结果目标化合物结构经MS、NMR及X-单晶衍射等确证。目标化合物的不对称还原反应收率达90.3%,e.e.%达99.04%,体外药理活性数据显示,S-构型目标化合物对微管蛋白聚合、HCT116和CCRF-CEM肿瘤细胞的抑制活性优于R-构型异构体及先导化合物22b,其IC_(50)分别达到0.41、0.14和0.001μmol/L。结论采用CBS不对称催化还原的方法是一条制备高光学纯度的手性目标化合物的合成方法;高活性的S构型异构体具有进一步研究的价值。Objective To synthesize the enantiomers of ( E)-6-methoxy-1-(3,4,5-trimethoxybenzylidene )-1,2,3,4-tetra-hydronaphthalen-2-ol,determine their structures by XRD and evaluate their anti-tumor activity in vitro.Methods The target compounds were prepared from 2,6-Dimethoxybenzoyl chloride.The key intermediate,(E)-6-methoxy-1-(3,4,5-trimethoxybenzylidene)-1,2,3,4-tetrahydronaphthalen-2-one,was obtained through Cornforth reduction and Knoevenael reaction ,and the final R,S compounds were got by CBS asymmetric reduction .The structure of the target compounds were determined by XRD .The target compounds were rested by anti-tu-bulin and anti-tumor assay.Results The structure of the target compounds were determined by 1 H NMR,13 C NMR,MS,and XRD analy-sis.The yield of asymmetric reduction reaction was 90.3%,e.e.%was 99.04%,in vitro anti-tumor assay showed all of the S isomer had stronger anticancer activity than the R isomer ,especially on CCRF-CEM cell(IC50 =1 nmol/L),HCT-116 cell(IC50 =0.14μmol/L) and inhibition of tubulin polymerization ( IC50 =0.41μmol/L) .Conclusion The CBS asymmetric reduction was a good way to get high-yield and high optical purity compound .The S isomer with outstanding anticancer activity was worth further research .
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.13